PD-L1 gene amplification and focality: relationship with protein expression

被引:5
|
作者
Jardim, Denis Leonardo [1 ]
Murugesan, Karthikeyan [2 ,3 ]
Elvin, Julia A. [3 ]
Huang, Richard S. P. [3 ]
Kurzrock, Razelle [4 ,5 ]
机构
[1] Hosp Sirio Libanes, Ctr Oncol, Sao Paulo, Brazil
[2] Fdn Med Inc, Canc Genom Res, Cambridge, MA USA
[3] Fdn Med Inc, Cambridge, MA USA
[4] WIN Consortium Personalized Canc Therapy, Dept Med, San Diego, CA USA
[5] Med Coll Wisconsin, Milwaukee, WI USA
关键词
Biomarkers; Tumor; Genetic Markers; Immunohistochemistry;
D O I
10.1136/jitc-2022-006311
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PD-L1 (CD274) amplification occurs in a small subset of malignancies and may predict anti-PD-1/PD-L1 immunotherapy responsiveness. We hypothesized that both copy number (CN) and focality of cancer-related PD-L1 amplifications impact protein expression, and, thus, analyzed solid tumors that underwent comprehensive genomic profiling between March 2016 and February 2022 at Foundation Medicine. PD-L1 CN alterations were detected using a comparative genomic hybridization-like method. PD-L1 CN changes were correlated with PD-L1 protein expression (DAKO 22C3 antibody) by immunohistochemistry (IHC). Overall, 60,793 samples were analyzed (most frequent histologies: lung adenocarcinoma (20%), colon adenocarcinoma (12%), lung squamous carcinoma (8%)). Using a definition of CD274 CN >= specimen ploidy +4 (6 copies), 1.21% of tumors (738/60,793) were PD-L1 amplified. Focality category distribution was as follows: <0.1 mB (n=18 (2.4%)), >= 0.1 to <4 mB (n=230 (31.1%)), >= 4 to <20 mB (n=310 (42%)), >= 20mB (n=180 (24.4%)). Lower levels of PD-L1 amplification (below specimen ploidy +4) were more frequently non-focal amplifications compared to higher levels. In addition, more focal amplification (<0.1 mB) correlated with higher PD-L1 IHC expression. Median tumor proportion score (TPS) for samples with PD-L1 amplification (ploidy >=+4) according to focality were 87.5% (<0.1 mB), 80% (>= 0.1 to <4 mB), 40% (>= 4 to <20 mB), 1% (>= 20mB). In specimens with PD-L1 ploidy less than +4, but highly focal (<0.1 mB), the 75th percentile of PD-L1 expression by TPS was 80%. Conversely, non-focal (>= 20 mB) PD-L1 amplification (ploidy >=+4) can present high PD-L1 expression (TPS >= 50%), albeit infrequently (0.09% of our cohort). In conclusion, PD-L1 expression measured by IHC is influenced by PD-L1 amplification level and focality. Further correlation between amplification, focality, protein expression and therapeutic outcome for PD-L1 and other targetable genes warrants exploration.
引用
收藏
页数:6
相关论文
共 50 条
  • [41] Expression of the Extracellular Domain of Mouse PD-L1 and Production of Antibodies to PD-L1
    Goryunova, M. S.
    Ryazantsev, D. Yu.
    Petrova, E. E.
    Kostenko, V. V.
    Makarova, A. O.
    Kholodenko, R. V.
    Ryabukhina, E. V.
    Kalinovsky, D. V.
    Kotsareva, O. D.
    Svirshchevskaya, E. V.
    RUSSIAN JOURNAL OF BIOORGANIC CHEMISTRY, 2024, 50 (06) : 2644 - 2656
  • [42] PD-L1 protein expression is a prognostic biomarker in breast cancer
    Wimberly, H.
    Schalper, K.
    Chen, L.
    Velcheti, V.
    Pusztai, L.
    Rimm, D.
    CANCER RESEARCH, 2013, 73
  • [43] Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma
    Yeo, Min-Kyung
    Choi, Song-Yi
    Seong, In-Ock
    Suh, Kwang-Sun
    Kim, Jin Man
    Kim, Kyung-Hee
    HUMAN PATHOLOGY, 2017, 68 : 103 - 111
  • [44] Programmed cell death ligand-1 protein expression and CD274/PD-L1 gene amplification in colorectal cancer: Implications for prognosis
    Lee, Kyu Sang
    Kim, Bo Hyung
    Oh, Heung-Kwon
    Kim, Duck-Woo
    Kang, Sung-Bum
    Kim, Hyunchul
    Shin, Eun
    CANCER SCIENCE, 2018, 109 (09): : 2957 - 2969
  • [45] PD-L1-Gene Expression by nCounter Correlates with PD-L1 Protein Expression in Advanced Non-Small Cell Lung Cancer (NSCLC)
    Cabrera, C.
    Aguado, C.
    Teixido, C.
    Pare, L.
    Castellvi, J.
    Lopez, L.
    Marin, E.
    Bernal, X.
    Martinez, D.
    Gimenez-Capitan, A.
    Vinolas, N.
    Yeste, Z.
    Baixeras, N.
    Roman, R.
    Molina-Vila, M.
    Reguart, N.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S927 - S927
  • [46] Highly Activated PD-1/PD-L1 Pathway in Gastric Cancer with PD-L1 Expression
    Saito, Hiroaki
    Kono, Yusuke
    Murakami, Yuki
    Shishido, Yuji
    Kuroda, Hirohiko
    Matsunaga, Tomoyuki
    Fukumoto, Yoji
    Osaki, Tomohiro
    Ashida, Keigo
    Fujiwara, Yoshiyuki
    ANTICANCER RESEARCH, 2018, 38 (01) : 107 - 112
  • [47] Clinicopathological significance of PD-L1 expression in colorectal cancer: Impact of PD-L1 expression on pFOXO1 expression
    Pyo, Jung-Soo
    Ko, Soo Hee
    Ko, Young San
    Kim, Nae Yu
    PATHOLOGY RESEARCH AND PRACTICE, 2020, 216 (02)
  • [48] PD-L1 and PD-L2 Protein Expression is Frequently Discordant in Breast Cancer
    Chaudhary, Lubna
    Jorns, Julie
    Sun, Yunguang
    Kamaraju, Sailaja
    Cheng, Yee Chung
    Kong, Amanda
    Yen, Tina
    Patten, Caitlin
    Cortina, Chandler
    Chervoneva, Inna
    Chitambar, Christopher
    Rui, Hallgeir
    CANCER RESEARCH, 2024, 84 (09)
  • [49] EXPRESSION OF PD-1, PD-L1 AND PD-L2 IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES AND ITS CLINIC RELATIONSHIP
    Geng, S.
    Weng, J.
    Deng, C.
    Li, M.
    Lu, Z.
    Wu, P.
    Huang, X.
    Lai, P.
    Du, X.
    LEUKEMIA RESEARCH, 2017, 55 : S112 - S112
  • [50] PD-L1 expression in colon cancer and its relationship with clinical prognosis
    Shan, Tao
    Chen, Shuo
    Wu, Tao
    Yang, Yi
    Li, Shunle
    Chen, Xi
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2019, 12 (05): : 1764 - 1769